XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Inclusion Criteria: * Must be 18 years of age or above. All races and ethnicities are eligible and no upper limit of age is specified. * Must have cytologically or histologically-confirmed unresectable melanoma that harbors a BRAF V600 mutation determined by pyrosequencing assay or equivalent genotyping assay in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory, meeting one of the following AJCC staging criteria: 1.) American Joint Committee on Cancer (AJCC) stage IV (Tany, Nany, M1a, b, or c); 2.) AJCC stage IIIB or IIIC with unresectable nodal/locoregional involvement. * Adequate hepatic, renal, and bone marrow function with parameters obtained within 4 weeks prior to initiation of study treatment. * Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. * Willing to give written informed consent per institutional guidelines and must be able to adhere to dose and visit schedules. * Negative serum pregnancy test within 7 days prior to commencement of dosing in premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥1 year. * Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician. * Treatment-naïve and previously treated patients will be included; however, patients may not have received a BRAF, Mitogen Activat…